Postdoctoral Fellow – Redox Biology, DNA damage response at NCI, Bethesda, Maryland

The Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH) is hiring a Postdoctoral Fellow – Redox Biology, DNA damage response in Bethesda, Maryland. Requires a Ph.D. or equivalent, or M.D. or equivalent.

Job Details

Organisation: Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH)

Lab/Branch/Program: Developmental Therapeutics Branch

Hiring Official/Investigator: Urbain Weyemi, Ph.D.

Date posted: 04 November 2026

Job location: Bethesda, Maryland, USA

Appointment type: Training position

Work schedule: Full-time (in-person)

Citizenship: US citizenship or permanent residency not required

Experience: The listing does not state a number of years of experience.

Job Description

A postdoctoral position is available with the Genomic Stability and Redox Metabolism group (PI: Urbain Weyemi, Ph.D.) within the Developmental Therapeutics Branch, CCR, NCI in Bethesda, Maryland, starting immediately. The group aims to understand the dialogue between genomic instability and redox metabolism in cancer. It applies genomics and metabolomics tools to assess redox vulnerabilities in cancer cells. The goal is to understand how cancer cells sense oxidative stress and overcome treatment with chemotherapeutic drugs targeting DNA damage response.

The overarching goal of the group is to define how redox metabolism cooperates with DNA damage response (DDR) pathways to promote resistance to genotoxic therapies and to exploit these dependencies for precision treatment. The DDR is essential for sensing and repairing genotoxic lesions, and is targeted by multiple clinically relevant agents, including inhibitors of DNA repair proteins such as ATR, ATM and PARPs, or radiotherapy (RT). However, durable clinical responses to DDR-targeted therapies are frequently limited by intrinsic or acquired resistance.

Major gaps remain in understanding how redox metabolism functionally influences DDR signaling to promote therapeutic responses; addressing this gap represents a critical unmet need in precision oncology. The central hypothesis is that redox-regulated enzymes and redox metabolites actively control DDR signaling, nuclear homeostasis and therapeutic response, thereby creating targetable vulnerabilities in cancer cells.

The group will test this hypothesis by employing functional genomics, proteomics, computational dependency mapping, mouse models, patient-derived xenografts and organoids, all coupled with functional assays.

Key Responsibilities

  • The successful applicant will use CRISPR-based screens and biochemical tools to study redox homeostasis in cancer cells.

Eligibility Criteria

  • Degree required: Ph.D. or equivalent, or M.D. or equivalent

Required Skills

  • A Ph.D. or M.D. degree that includes training in molecular biology and biochemistry
  • The group is looking for applicants with solid expertise in Redox Biology and biochemistry, with some experience in Bioinformatics.

Preferred Skills

  • Training in bioinformatics will be considered a plus.
  • Some experience with animal studies will be greatly valued.

Salary

Starting stipend: $68,544

Documents Required

  • CV/Resume
  • 3 References

How to Apply

Contact: Urbain Weyemi, Ph.D. – [email protected]

Additional Information

Training opportunities are augmented by collaborations with colleagues, physicians and pharmacologists from the intramural and extramural communities. Fellows are encouraged to take advantage of formal, focused courses (e.g., training in bioinformatics and translational research), actively engage in mentoring and participate in a variety of community activities, including the NIH’s DNA Repair Interest Group and the NCI’s Center of Excellence in Chromosome Biology.

About the NCI Center for Cancer Research

The Center for Cancer Research (CCR) is home to nearly 220 basic and clinical research groups located on two campuses just outside Washington, D.C. CCR is part of the National Cancer Institute (NCI) and makes up the largest component of the research effort at the National Institutes of Health (NIH). Centrally supported by long-term funding and a culture of complete intellectual freedom, CCR scientists pursue the most important and challenging problems in cancer research, collaborating with academic and commercial partners and advocacy groups across the world to prevent, diagnose and treat cancer and HIV/AIDS.

The CCR research portfolio covers the full spectrum of biological and biomedical research, from basic to translational and clinical, and its clinical trials are conducted in the NIH Clinical Center, the world’s largest hospital dedicated to clinical research. DHHS, NIH and NCI are equal opportunity employers.

CLICK HERE FOR THE ORIGINAL NOTIFICATION / APPLY ONLINE

To apply, contact Urbain Weyemi, Ph.D. at [email protected].